today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a ...

"We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit Bonum and ...

(Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today ...

(Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ...

During opening day at the local baseball stadium, PI Sam Blackman and Nakayla Robertson, his... At the start of de Castrique’s nicely plotted seventh Sam Blackman mystery (after 2017’s Hidden ...

Samuel Blackman, M.D., Ph.D., who is one of the co-founders and currently the Head of Research & Development, has informed the company of his intention to retire by the end of 2024. Dr.